contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Realfiction Holding har udviklet display teknologi, der muliggør produktion af 3D-skærme, som kan benyttes af flere på samme tid, uden brug af briller. Alle teknologier er klar til licensering, og Realfiction forfølger nu kommercielle licensaftaler og samarbejdsaftaler, der kan føre til masseproduktion. Realfictions patentportefølje for deres Directional Pixel Technology består af 15 patentfamilier med ansøgninger indgivet i flere lande.

Realfiction

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

NeoDynamics AB meddelte i går, at det indgår partnerskab med den globale distributions- og logistikgigant Uniphar Group for at sikre en succesfuld lancering af NeoNavia® i USA, dets innovative pulsbiopsisystem.  NeoDynamics couldn’t be more pleased to be partnering with Uniphar, a proven global partner to pharma and MedTech companies. Leveraging Uniphar’s customer service, logistics management and digital technology will allow us to aggressively hit the US market. The relationship with Uniphar is a key corporate development as we put all the pieces in place for the successful US launch of NeoNavia, fortæller Anna Eriksrud CEO af NeoDynamics.  Endnu et vigtig skridt for NeoDynamics i forbindelse med deres lancering af puls biopsi-systemet Neonavia på det amerikanske marked. Efter FDA godkendelsen i efteråret 2022 er der kommet fart på forberedelserne op til lanceringen. De har fået ledelse, partner til hjælp med lanceringen og nu også en distributionspartner på plads. Det totale marked for bryst biopsi vurderes til USD 830 mio. i 2025. Læs hele meddelelsen her.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  NeoDynamics AB (publ) er en svensk medicinsk teknologivirksomhed dedikeret til at fremme diagnosticering og behandling af brystkræft. Virksomhedens første produkt NeoNavia®, et nyt innovativt pulsbiopsisystem til ultralydsstyret vævsprøvetagning, er i øjeblikket ved at blive introduceret på markedet. Biopsisystemet er bygget på en patenteret pulsteknologi, baseret på forskning ved Karolinska Institutet i Sverige. NeoNavia er evalueret for brystkræftdiagnose på førende klinikker i Storbritannien, Tyskland og Sverige. Pulsbiopsisystemet er blevet brugt til vævsprøvetagning i bryst og aksillære lymfer hos over 500 patienter. English:  NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breast and axilla in over 500 patients.

NeoDynamics

Dagens aktienyheder 06/02 med Realfiction - Leaders in Mixed Reality og NeoDynamics

Dagens aktienyheder 06/02:&nbsp;<a href="https://www.linkedin.com/company/realfition/" data-attribute-index="0" data-entity-type="MINI_COMPANY">Realfiction - Leaders in Mixed Reality</a>&nbsp;og&nbsp;<a href="https://www.linkedin.com/company/neodynamics-ab/" data-attribute-index="2" data-entity-type="MINI_COMPANY">NeoDynamics</a> <a href="https://www.linkedin.com/company/realfition/" data-attribute-index="4" data-entity-type="MINI_COMPANY">Realfiction - Leaders in Mixed Reality</a>&nbsp;meddelte i g&aring;r efter markedsluk, at selskabet har indg&aring;et en l&aring;neaftale p&aring; op til SEK 35 millioner med Formue Nord Fokus A/S. L&aring;neaftalen er vigtig for&nbsp;<a href="https://www.linkedin.com/company/realfition/" data-attribute-index="6" data-entity-type="MINI_COMPANY">Realfiction - Leaders in Mixed Reality</a>, da likviditeten sikrer, at selskabet over de kommende 18 m&aring;neder kan udnytte mulighederne kommercielt og p&aring; IP-portef&oslash;ljen p&aring; selskabets Directional Pixel Technology. L&aelig;s mere om l&aring;neaftalen her: <a class="x1i10hfl xjbqb8w x1ejq31n xd10rxx x1sy0etr x17r0tee x972fbf xcfux6l x1qhh985 xm0m39n x9f619 x1ypdohk xt0psk2 xe8uvvx xdj266r x11i5rnm xat24cr x1mh8g0r xexx8yu x4uap5 x18d9i69 xkhd6sd x16tdsg8 xggy1nq x1a2a7pz xt0b8zv x1heor9g x1bvjpef" tabindex="-1" role="link" href="https://www.inderes.dk/analyst-comments/realfiction-secures-loan-facility-and-extends-financial-runway" target="_blank" rel="nofollow noopener">https://www.inderes.dk/analyst-comments/realfiction-secures-loan-facility-and-extends-financial-runway</a> <a href="https://www.linkedin.com/company/neodynamics-ab/" data-attribute-index="9" data-entity-type="MINI_COMPANY">NeoDynamics&nbsp;</a>har udsendte en meddelelse fredag vedr&oslash;rende afholdt ekstraordin&aelig;r generalforsamling fredag den 2. februar, hvor det blev vedtaget at foretage et omvendt aktiesplit i forholdet 100:1 og reducere antallet af aktier til at udg&oslash;re mellem nominelt SEK 2,8 millioner og 11,2 millioner for &oslash;ge den nominelle aktiest&oslash;rrelse og selskabets aktiekurs. Aktiesplittet foretages den 19. februar, og derefter forventes den tidligere annoncerede fortegningsemission at blive gennemf&oslash;rt i perioden 1. til 15. marts med henblik p&aring; at tilf&oslash;re selskabet SEK 25 millioner. Disclaimer:&nbsp;<a href="https://www.linkedin.com/company/hcandersencapital/" data-attribute-index="11" data-entity-type="MINI_COMPANY">HCA - HC Andersen Capital</a>&nbsp;modtager betaling fra selskaberne for en Digital IR aftale. Jesper Thomsen - 06/02-2024 kl. 09:04.

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!